Odyral (Dorzolamide)

Dorzolamide is used to reduce intra‑ocular pressure in several glaucoma‑related conditions.

• Open‑angle glaucoma: reduces intra‑ocular pressure, helping to preserve visual field and slow disease progression.
• Ocular hypertension: lowers pressure to prevent development of glaucoma.
• Secondary glaucoma: helps control pressure when elevated due to other ocular disorders.

• Dorzolamide inhibits carbonic anhydrase isoenzymes in the ciliary body epithelium. By blocking the enzyme, the production of aqueous humor is decreased, leading to reduced intra‑ocular pressure. The inhibition is reversible and localized to ocular tissues, providing targeted pressure control without systemic carbonic anhydrase inhibition. This mechanism results in a sustained decrease in fluid accumulation within the anterior chamber, thereby maintaining pressure within therapeutic ranges over the dosing interval.

Dorzolamide may cause ocular and systemic adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects

• Eye irritation or discomfort: mild burning or stinging after instillation.
• Blurred vision: temporary reduction in visual clarity.
• Taste disturbance: bitter taste sensation.
• Headache: mild to moderate.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or anaphylaxis.
• Corneal edema: swelling of the cornea affecting vision.
• Persistent ocular pain: prolonged discomfort requiring medical review.

When using Odyral, consider the following precautions.

• Pregnancy: safety not established; use only if benefit outweighs risk.
• Breastfeeding: unknown; consider potential risk to infant.
• Renal impairment: monitor renal function as the drug is eliminated renally.
• Concurrent ocular surgery: discontinue prior to procedure to avoid wound healing complications.
• Allergy: avoid if known hypersensitivity to dorzolamide or sulfonamides.
• Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid)

• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive effect may cause excessive intra‑ocular pressure lowering.
• Topical beta‑blockers: combined use may increase risk of ocular hypotension.
• Sulfonamide antibiotics: cross‑reactivity may trigger allergic response.

Moderate Interactions (Monitor Closely)

• Topical prostaglandin analogues: may affect efficacy; monitor pressure.
• Systemic diuretics: may alter electrolyte balance; observe renal function.
• Anticholinergic eye drops: possible reduced drug absorption.